MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Total Non-current Liabilities
All obligations due after more than one year.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 16.4% from a year ago
Total non-current liabilities stood at $4.67M at the end of Q1 FY2026, down 16.4% from a year earlier and down 4.9% from the prior quarter. Over 3 fiscal years it compounded at -6.1% a year.
Context
- Total non-current liabilities amounted to 1.1% of total assets at the end of Q1 FY2026, down 3.9 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -16.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.91M USD
- Year-over-year change
- -15.3%
- 3-year CAGR
- -6.1%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.91M | -15.3% |
| FY2024 | 2024-12-31 | 5.8M | +6.9% |
| FY2023 | 2023-12-31 | 5.43M | -8.3% |
| FY2022 | 2022-12-31 | 5.92M | — |
Total Non-current Liabilities vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 total non-current liabilities of $4.67M is the 8th highest of the 11 companies compared; the peer median is $15.69M.
- Its year-over-year change of -16.4% is the 5th highest of 9, against a peer median of -16.4%.
- Total non-current liabilities amounts to 1.1% of total assets for MPLT, versus a peer median of 4.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $292.69B | +487717.0% | +47.5% | 307.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $53.08M | — | -59.9% | 34.5% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $38.52M | -5.8% | +226.1% | 3.6% |
| Mar 2026 | $25.75M | -75.4% | +47.7% | 9.2% | |
| Mar 2026 | $19.78M | -22.6% | -35.7% | 7.2% | |
| Mar 2026 | $11.61M | -11.2% | -9.2% | 5.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $8.19M | +19.8% | -5.8% | 1.6% |
| Mar 2026 | $4.67M | -16.4% | -6.1% | 1.1% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3.88M | -21.7% | -56.2% | 1.0% |
| Mar 2026 | $75K | -76.7% | -57.1% | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding MPLT) | $15.69M | -16.4% | -9.2% | 4.4% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.